Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Forward Printable StoryPrint Comment




Artificial Intelligence Homepage

Health Quest sets out to boost participation in clinical trials with IBM Watson

AI and MRs at birth can predict cognitive development at age 2, UNC study finds

Researchers use algorithm from Netflix challenge to speed up biological imaging

iCAD reports strong momentum of ProFound AI, its artificial intelligence-based solution for digital breast tomosynthesis

Bay Labs announces new data that evaluates accuracy, efficiency and reproducibility of EchoGPS and AutoEF AI software

A boost for medical imaging AI in India: India-Israel innovation fund (I 4 F) greenlights new initiative

LEAD releases innovative document and medical imaging technologies

Lucence diagnostics to develop AI tools for liver cancer treatment

Nikon instruments launches new digital pathology solution in partnership with OptraSCAN at USCAP 2019

AI maps out brain through course of Alzheimer's disease

ScreenPoint Medical and Volpara Health Technologies sign MOU to partner in bringing AI breast imaging solutions to the clinic

Press releases may be edited for formatting or style
CHICAGO (PRWEB) NOVEMBER 29, 2018 -- ScreenPoint Medical announced today that it has signed a Memorandum of Understanding (MOU) with Volpara Health Technologies. Volpara will deliver ScreenPoint’s AI-based products to customers as part of its expanding VolparaEnterprise AI cloud ecosystem. Together, the two companies expect to improve the clinical performance of mammography and drive the earlier detection of breast cancer. The partnership will leverage Volpara’s growing footprint in the breast imaging marketplace and will provide a unique opportunity for ScreenPoint to enter the US market.

ScreenPoint recently announced that it has received 510(k) Clearance from the U.S. Food & Drug Administration (FDA) for Transpara™ detection and decision support software, designed to assist radiologists with the reading of screening mammograms. Transpara is the first AI application for detecting breast cancer in screening mammograms to gain 510(k) Clearance from the FDA, based on its unique functionality which interactively provides support for detection and diagnosis.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Compared to traditional mammography CAD products, ScreenPoint’s Decision Support product Transpara delivers much more clinically useful information to the radiologist,” said Dr. Ritse Mann, breast imaging specialist at Radboud University Medical Center, Nijmegen, NL, who uses the system clinically and evaluated its performance in several studies, “I can use Transpara as a second reader and its opinion is as good as when I would ask a colleague.”

Professor Nico Karssemeijer, CEO of ScreenPoint and well-known for his pioneering work in computer-aided detection and breast imaging said, "Being a co-founder, I worked with Volpara as advisor in the past and I am excited that ScreenPoint and Volpara will now partner to bring our AI solution Transpara for breast cancer detection to the US market. Volpara is well-established in the breast space in the US, and together the two companies can work to help breast practices improve cancer detection and streamline mammography reading."

Dr Ralph Highnam, CEO of Volpara Health Technologies said "Professor Karssemeijer’s seminal works on automated detection, and more recently machine learning and AI, is globally recognized as first class, and we're delighted to have ScreenPoint join our common cause. Adding an important product like Transpara Decision Support is a perfect step for us. It enriches our offering to breast imaging centers in the US and abroad, and expands the VolparaEnterprise ecosystem as we build a platform for delivering well-curated AI and other software applications for our customers.”

About ScreenPoint Medical BV
ScreenPoint Medical develops image analysis technology for automated reading of mammograms and digital breast tomosynthesis exams, exploiting Big Data, Deep Learning and the latest developments in Artificial Intelligence. ScreenPoint Medical was founded in 2014 by Nico Karssemeijer and Michael Brady, two experts in breast imaging, machine learning, computer vision, and computer-aided detection. The main office is in Nijmegen, The Netherlands. https://www.screenpoint-medical.com/

Artificial Intelligence Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.